Zeo ScientifiX Reports 32.7% Revenue Increase to $1.446 Million, Net Loss Improves

Zeo ScientifiX, Inc. reported a significant increase in revenue for the three months ending January 31, 2026, achieving $1.446 million, a 32.7% rise from $1.090 million in the same period the previous year. The growth was attributed to heightened sales of its allogenic aesthetic biologic products and the Patient Pure X™ (PPX™) service platform. Despite the revenue increase, the company recorded a net loss of $852,000, an improvement from the $1.243 million loss reported in the prior year, reflecting a reduction in operational losses.

The company's financial position showed notable changes compared to the previous fiscal period. Total current assets rose to $2.007 million from $958,000, primarily due to increased cash reserves, which climbed to $1.030 million from $221,000. However, total liabilities remained relatively stable at $2.954 million, slightly up from $2.950 million. The stockholders' deficit improved significantly, decreasing to $383,000 from $1.423 million, indicating a positive shift in the company's equity position.

Strategically, Zeo has been active in expanding its product offerings and compliance with new regulations. The company is focusing on the implications of Florida's new "stem cell therapy" law, effective July 1, 2025, which allows for the administration of non-FDA-approved stem cell therapies. This regulatory change is expected to create new market opportunities for Zeo's products. Additionally, the company has initiated a clinical study to evaluate the safety and efficacy of PPX™ in treating musculoskeletal joint pathologies, with plans to enroll up to 350 patients.

Operationally, Zeo's engagement metrics reflect a growing customer base, with increased sales representative efforts and participation in industry conferences contributing to heightened product awareness. The company reported a total of 7,614,941 shares outstanding as of January 31, 2026, up from 6,747,441 shares a year earlier. However, the company continues to face challenges, including a working capital deficit of $879,000 and reliance on external funding to support ongoing operations and research initiatives.

Looking ahead, Zeo's management expressed caution regarding the company's ability to continue as a going concern, given its accumulated deficit and ongoing losses. The company is actively seeking additional investment capital to fund its operations and research and development costs. While the new regulatory environment in Florida presents potential growth opportunities, the company acknowledges the risks associated with its current financial position and the need for successful execution of its strategic initiatives to stabilize revenue streams.